The estimated Net Worth of Stephen Kanes is at least $17 Million dollars as of 4 September 2019. Stephen Kanes owns over 6,000 units of Sage Therapeutics Inc stock worth over $62,107 and over the last 10 years he sold SAGE stock worth over $12,976,351. In addition, he makes $3,969,930 as Chief Medical Officer at Sage Therapeutics Inc.
Sign up
Stephen Kanes SAGE stock SEC Form 4 insiders trading
Stephen has made over 12 trades of the Sage Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 6,000 units of SAGE stock worth $2,700 on 4 September 2019.
The largest trade he's ever made was selling 44,000 units of Sage Therapeutics Inc stock on 10 January 2018 worth over $7,795,920. On average, Stephen trades about 6,088 units every 72 days since 2014. As of 4 September 2019 he still owns at least 8,292 units of Sage Therapeutics Inc stock.
You can see the complete history of Stephen Kanes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Kanes biography
Dr. Stephen J. Kanes M.D. Ph.D. serves as Chief Medical Officer of the Company. From 2012 to 2013, he served as the Chair of the neuroscience safety knowledge group at AstraZeneca plc, or AstraZeneca. From 2011 to 2013, Dr. Kanes served as the Executive Director—Therapeutic Area Clinical Director for the inflammation, neuroscience and respiratory GMED Division of AstraZeneca. From 2008 to 2012, Dr. Kanes served as the Medical Science Senior Director for the neuroscience established brands and emerging anesthesia Group Product Team and in other positions of increasing responsibility in the Neuroscience Discovery Medicine, early and late development groups of AstraZeneca. From 1999 to 2006, Dr. Kanes served as a practicing psychiatrist. Dr. Kanes was a faculty member in the Psychiatry Department at the University of Pennsylvania School of Medicine, where he continues to serve as an adjunct assistant professor of psychiatry. Dr. Kanes has authored or co-authored more than 30 peer-reviewed publications, and has served as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics, and Biological Psychiatry. Dr. Kanes received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York—Stony Brook. Dr. Kanes completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.
What is the salary of Stephen Kanes?
As the Chief Medical Officer of Sage Therapeutics Inc, the total compensation of Stephen Kanes at Sage Therapeutics Inc is $3,969,930. There are 2 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
How old is Stephen Kanes?
Stephen Kanes is 55, he's been the Chief Medical Officer of Sage Therapeutics Inc since 2013. There are 13 older and 4 younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.
What's Stephen Kanes's mailing address?
Stephen's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.
Insiders trading at Sage Therapeutics Inc
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen und Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
What does Sage Therapeutics Inc do?
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
What does Sage Therapeutics Inc's logo look like?
Complete history of Stephen Kanes stock trades at Sage Therapeutics Inc
Sage Therapeutics Inc executives and stock owners
Sage Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Jonas,
President, Chief Executive Officer and Director -
Michael Cloonan,
Chief Operating Officer -
Stephen Kanes,
Chief Medical Officer -
Anne Cook,
Senior Vice President, General Counsel, Secretary -
Kimi Iguchi,
Chief Financial Officer, Treasurer -
Albert Robichaud,
Chief Scientific Officer -
Elizabeth Barrett,
Independent Director -
George Golumbeski,
Independent Director -
Dr. Jeffrey M. Jonas,
Chief Innovation Officer, Chair of the Science & Technology Forum and Director -
Kevin Starr,
Independent Chairman of the Board -
Michael Cola,
Independent Director -
James Frates,
Independent Director -
Steven Paul,
Independent Director -
Geno Germano,
Independent Director -
Asha Nayak,
Independent Director -
Anne Marie Cook,
Sr. VP, Gen. Counsel & Sec. -
Dr. Albert J. Robichaud Ph.D.,
Chief Scientific Officer -
Kimi E. Iguchi,
CFO & Treasurer -
Barry E. Greene,
Pres, CEO & Director -
Barry Greene,
Director -
Dr. Jim Doherty Ph.D.,
Chief Devel. Officer -
Dr. Amy Schacterle Ph.D.,
Sr. VP of R&D Strategy and Bus. Management -
Erin E. Lanciani,
Chief People & Experience Officer -
Helen Rubinstein,
Investor Relations Officer -
Matt Lasmanis,
Chief Technology & Innovation Officer -
Rock Ventures Ii, L.P.Third...,
-
Howard H Pien,
-
Thomas Anderson,
See Remarks -
Robert Nelsen,
Director -
Venture Fund Vii Lparch Ven...,
-
Rock Ventures Ii, L.P.Third...,
-
Laura Gault,
Chief Medical Officer -
Jessica Federer,
-
Christopher Benecchi,
Chief Business Officer